Value of chemotherapy for patients with locoregional breast cancer recurrence

Liz Meszaros, MDLinx

San Antonio Breast Cancer Symposium 2017

San Antonio, Texas, United States | December 05-09, 2017

Although chemotherapy can positively impact patient outcomes after locoregional recurrence of breast cancer, this will generally occur only in patients with HR-negative (HR-) disease rather than those with HR-positive (HR+) disease, according to William Gradishar, MD, professor of medicine, Northwestern University, Evanston, IL.

Dr. Gradishar stressed, however, that even in patients with HR- disease, data on th effects of chemotherapy are limited, but suggest that HR- patients who undergo chemotherapy will demonstrate improved disease-free survival, and possibly better overall survival.

In HR-positive disease, chemotherapy does not seem to have any effect, he added.

“We have to individualize and be selective about where we use chemotherapy,” Dr. Gradishar concluded.

All Interviews

From this Conference

3:02

How to approach your patients to improve adherence to therapy
With recent approvals for new oral mTOR and CDK 4/6 inhibitors, patients with cancer are more responsible for treatment adherence, and it is important to keep the lines of...
Angela DeMichele, MD, MSCE
5:57

Exploring locoregional recurrence of breast cancer
For locoregional recurrence of breast cancer, there is no standard of care because there are so few patients in whom this occurs.
William Gradishar, MD
1:11

Breast imaging can predict cancer recurrence
At the 2018 Best of SABCS-NY, Sheldon Feldman, MD, FACS, chief of breast surgery and breast surgical oncology, Montefiore-Einstein Cancer Center, New York, director of breast...
Sheldon Feldman, MD, FACS

2:36

A look back at SABCS 2017: Overtreatment can result in lifelong complications
Researchers from around the world gathered at the 2017 San Antonio Breast Cancer Symposium to present research that would change the way we view breast cancer.
Sheldon Feldman, MD, FACS
7:15

Seamless designs for clinical trials: A new wave in drug development, explained
With the movement toward developing more targeted therapies, the FDA has updated its drug development system to include what they have designated as ‘seamless...
Tatiana Prowell, MD
2:51

Multidisciplinary management of locoregional breast cancer recurrence
Locoregional recurrences of breast cancers are rare, but when they do occur, can be challenging and typically require a multidisciplinary evaluation.
William Gradishar, MD

This activity is not sanctioned by, nor a part of, the San Antonio Breast Cancer Symposium 2017.